Checkmate Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger, by and among the company, Regeneron Pharmaceuticals, Inc. and Scandinavian Acquisition Sub, Inc. (Parent) and a wholly owned subsidiary of Parent (Purchaser), dated as of April 18, 2022. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, on May 31, 2022, Purchaser completed a cash tender offer (the Offer") to acquire all of the issued and outstanding shares of the common stock, par value $0.0001 per share, of the company at a price per share of $10.50, to be paid to the seller in cash, without interest and subject to reduction for any applicable withholding of taxes required by applicable law. At the Effective Time, each of Alan Bash, Peter Colabuono, Keith Flaherty, Alan Fuhrman, Oren K. Isacoff, Michael Powell, Jon Wigginton and Joy Yan resigned and ceased to be directors of the Company and members of any committee of the Company's Board of Directors.

Effective immediately following these resignations, Nouhad Husseini became the sole director of the Company. In addition, in connection with the closing of the Merger, the Company's Board of Directors appointed Nouhad Hussieni as Managing Director.